Study S000767
Chinese People's Liberation Army General Hospital
Registration
Registered primary outcomes
- main adverse cardiovascular events [Followed up for 6 months after enrolled in the study]
Linked records (13)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0022060 | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, The New England journal of medicine | 2016 | Randomized trial | PMID 27295427DOI | registry reference BACKGROUND:27295427 |
| R0025982 | Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Chen WR, Endocrine | 2016 | Randomized trial | PMID 26573925DOI | registry reference BACKGROUND:26573925 |
| R0026048 | Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Chen WR, International journal of cardiology | 2016 | Randomized trial | PMID 26849684DOI | registry reference BACKGROUND:26849684 |
| R0026061 | Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways. Zhang Y, Free radical biology & medicine | 2016 | Other | PMID 27038735DOI | registry reference BACKGROUND:27038735 |
| R0020721 | Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Chen WR, American heart journal | 2015 | Randomized trial | PMID 26542491DOI | registry reference BACKGROUND:26542491 |
| R0026736 | Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Kim SH, Diabetes care | 2013 | Randomized trial | PMID 23835684DOI | registry reference BACKGROUND:23835684 |
| R0021573 | Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. Gejl M, The Journal of clinical endocrinology and metabolism | 2012 | Randomized trial | PMID 22544917DOI | registry reference BACKGROUND:22544917 |
| R0023502 | Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Lønborg J, European heart journal | 2012 | Randomized trial | PMID 21920963DOI | registry reference BACKGROUND:21920963 |
| R0017606 | Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Zinman B, Diabetes care | 2009 | Randomized trial | PMID 19289857DOI | registry reference BACKGROUND:19289857 |
| R0019848 | Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Nauck M, Diabetes care | 2009 | Randomized trial | PMID 18931095DOI | registry reference BACKGROUND:18931095 |
| R0021038 | GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Noyan-Ashraf MH, Diabetes | 2009 | Preclinical | PMID 19151200DOI | registry reference BACKGROUND:19151200 |
| R0025460 | Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Timmers L, Journal of the American College of Cardiology | 2009 | Randomized trial | PMID 19195607DOI | registry reference BACKGROUND:19195607 |
| R0027526 | Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Garber A, Lancet (London, England) | 2009 | Randomized trial | PMID 18819705DOI | registry reference BACKGROUND:18819705 |